Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
- Associated Therapies
- -
Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT02729194
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
- First Posted Date
- 2016-02-25
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT02691767
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT02638428
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
- Conditions
- High Grade SarcomaRecurrent Malignant Peripheral Nerve Sheath TumorMetastatic Undifferentiated Pleomorphic SarcomaStage III Uterine Corpus Leiomyosarcoma AJCC v8Metastatic LeiomyosarcomaRecurrent Synovial SarcomaRecurrent Undifferentiated Pleomorphic SarcomaStage IVA Uterine Corpus Leiomyosarcoma AJCC v8Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8Metastatic Malignant Peripheral Nerve Sheath Tumor
- Interventions
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 151
- Registration Number
- NCT02601209
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States
Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients
- Conditions
- Interventions
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT02575066
- Locations
- 🇬🇧
Royal Marsden Hospital, London, United Kingdom
🇳🇱Leids Universitair Medisch Centrum, Leiden, Netherlands
🇳🇱Antoni van Leeuwenhoek, Amsterdam, Netherlands
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-10-12
- Target Recruit Count
- 4
- Registration Number
- NCT02560012
- Locations
- 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States
Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 47
- Registration Number
- NCT02555748
- Locations
- 🇫🇷
CHU DE BORDEAUX - Hôpital Saint-André, Bordeaux, France
🇫🇷Institut Claudius Regaud, Toulouse, France
🇫🇷CHU DE LIMOGES - Hôpital Dupuytren, Limoges, France
Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT02450136
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
- Conditions
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT02406521
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 72
- Registration Number
- NCT02393820
- Locations
- 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷CHU Bordeaux, Bordeaux, France
🇫🇷Gustave Roussy, Villejuif, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.